Divi's Labs gets one USFDA observation for Visakhapatnam facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-07-19 11:58 GMT | Update On 2024-07-19 11:58 GMT
Telangana: Divi's Laboratories Limited has received one procedural observation from the US Food and Drug Administration (USFDA) at the conclusion of a general cGMP inspection of the Company's Unit-II manufacturing facility at Chippada Village, Bheemunipatnam Mandal, Visakhapatnam, Andhra Pradesh.
The inspection took place from July 11, 2024 to July 19, 2024.
"The US-FDA inspection is successfully completed with one procedural observation, which will be addressed in the stipulated period of time", the company informed in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd